Vaccines - HIV

"An ACTG Phase Ia Safety and Pharmacokinetic Trial of Immunotherapy with the anti-CD4 Binding Site Human Monoclonal Antibody F105."

Published in Vaccine Weekly, February 20th, 1995

According to an abstract presented by the authors to the 2nd National Conference on Human Retroviruses and Related Infections, held January 29 - February 2, 1995, in Washington, DC, "F105 is an IgGK, human monoclonal antibody reactive with the CD4 binding site of HIV-1 gp120. A Phase Ia study of immunotherapy with F105 was performed in HIV-1 seropositive, asymptomatic volunteers with CD4 counts >500 and <200/mm³. F105 was given as a single, 1 hour, intravenous infusion. Recipients were monitored for safety and pharmacokinetics over a period of eight weeks. Four subjects, each, were treated at one of two doses, 100 or 500 mg/M². F105 plasma levels were...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1995-02-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry